Patients with higher Ki-67% and blastoid morphology are often excluded in large population-scaled clinical trials in MCL due to lack of volume; therefore, an understanding of their association with aberrant immunophenotypes and clinical features will provide valuable insight for future study design, including novel agents and cell therapy [9]. The gene discussed is MKI67; the disease is mantle cell lymphoma.